MedImmune LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1987-01-01

Employees: 5K

Market Cap: -

Website: http://medimmune.com

Clinical Trials

A Study to Evaluate a Single Intravenous Dose of Motavizumab for the Treatment of Children Hospitalized With Respiratory Syncytial Virus (RSV) Illness

Not Applicable

Completed

Conditions: RSV Illness in ≤12 Months of Participants

Interventions: Other: Placebo
Biological: Motavizumab

First Posted Date: 2007-01-11

Last Posted Date: 2021-08-27

Lead Sponsor: MedImmune LLC

Target Recruit Count: 118

Registration Number: NCT00421304

Locations: 🇵🇦
Research Site, Ciudad de Panama, Panama

A Study to Evaluate the Efficacy of MEDI-528 on Late Asthmatic Response With Atopic Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Biological: MEDI-528 9 mg/kg
Other: Placebo

First Posted Date: 2006-11-01

Last Posted Date: 2013-12-11

Lead Sponsor: MedImmune LLC

Target Recruit Count: 30

Registration Number: NCT00394654

Locations: 🇨🇦
McMaster University, Hamilton, Ontario, Canada
🇨🇦
University of Saskatchewan, Saskatoon, Saskatchewan, Canada
🇨🇦
Hopital Laval, Quebec, Canada

Study to Evaluate the Incidence of Hospitalizations and Respiratory Tract Infections in Premature Infants

Completed

Conditions: Respiratory Syncytial Virus Infections

First Posted Date: 2006-10-06

Last Posted Date: 2009-02-04

Lead Sponsor: MedImmune LLC

Target Recruit Count: 346

Registration Number: NCT00384462

Locations: 🇺🇸
Pediatric Associates of Dayton, Inc., Kettering, Ohio, United States
🇺🇸
Driscoll Children's Hospital, Corpus Christi, Texas, United States
🇺🇸
Georgia Pediatric Pulmonology Associates, Atlanta, Georgia, United States

and more 55 locations

An Epidemiological Study to Evaluate the RSV-Associated Lower Respiratory Track in Infections in Infants

Completed

Conditions: Pneumonia
Respiratory Infections
Bronchiolitis
Apnea

Interventions: Other: Emergency Dept. Subjects with LRI or Apnea

First Posted Date: 2006-08-29

Last Posted Date: 2009-03-17

Lead Sponsor: MedImmune LLC

Target Recruit Count: 2048

Registration Number: NCT00369759

Locations: 🇺🇸
Children's National Medical Center, Baltimore, Maryland, United States
🇺🇸
University of Maryland, Baltimore, Maryland, United States
🇺🇸
Hurley Medical Center, Flint, Michigan, United States

and more 33 locations

Study to Evaluate the Safety of MEDI-534 Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3) in Healthy Children

Phase 1

Completed

Conditions: Healthy

Interventions: Biological: MEDI-534

First Posted Date: 2006-06-28

Last Posted Date: 2008-09-03

Lead Sponsor: MedImmune LLC

Target Recruit Count: 120

Registration Number: NCT00345670

Locations: 🇺🇸
Heart of America Research, Topeka, Kansas, United States
🇺🇸
Edinger Medical Group, Fountain Valley, California, United States
🇺🇸
University of Maryland Pediatric Ambulatory Center, Baltimore, Maryland, United States

and more 8 locations

A Study to Evaluate the Shedding and Safety of Trivalent Influenza Virus Vaccine Live, Intranasal in Infants and Young Children

Phase 2

Completed

Conditions: Healthy

Interventions: Biological: Trivalent influenza virus vaccine live, intranasal

First Posted Date: 2006-06-26

Last Posted Date: 2017-07-24

Lead Sponsor: MedImmune LLC

Target Recruit Count: 200

Registration Number: NCT00344305

Locations: 🇺🇸
Little Rock Allergy & Asthma Clinic, PA, Little Rock, Arkansas, United States
🇺🇸
Pediatric and Adolescent Medicine, PA (PAMPA), Marietta, Georgia, United States
🇺🇸
Kentucky Pediatrics/Adult Research, Bardstown, Kentucky, United States

and more 11 locations

Study To Evaluate the Safety of Bivalent Vaccine

Phase 3

Completed

Conditions: Healthy

First Posted Date: 2006-05-12

Last Posted Date: 2007-07-18

Lead Sponsor: MedImmune LLC

Target Recruit Count: 300

Registration Number: NCT00325481

Locations: 🇺🇸
Heathcare Discoveries, Inc., San Antonio, Texas, United States
🇺🇸
Radiant Research, Daytona Beach, Daytona Beach, Florida, United States
🇺🇸
Radiant Research, Portland, Oregon, United States

Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) Season

Phase 2

Completed

Conditions: Respiratory Syncytial Virus Infections
Chronic Lung Disease and <= 24 Months of Age or
Premature With Gestational Age <=35 Weeks and <=6 Months of Age

Interventions: Biological: Motavizumab, palivizumab
Biological: Palivizumab, motavizumab
Biological: Motavizumab

First Posted Date: 2006-04-20

Last Posted Date: 2012-12-11

Lead Sponsor: MedImmune LLC

Target Recruit Count: 260

Registration Number: NCT00316264

Locations: 🇦🇺
Neonatalogy John Hunter Hospital, New Lambton Heights, New South Wales, Australia
🇨🇱
Hospital San Jose, Independencia, Santiago, Chile
🇨🇱
Hospital Padre Hurtado, Santiago, Chile

and more 16 locations

Safety and Tolerability of MEDI-545 in Patients Who Have Systemic Lupus Erythematosus (SLE)

Phase 1

Completed

Conditions: Lupus

Interventions: Biological: MEDI 545
Biological: MEDI-545

First Posted Date: 2006-03-07

Last Posted Date: 2007-12-18

Lead Sponsor: MedImmune LLC

Target Recruit Count: 45

Registration Number: NCT00299819

Locations: 🇺🇸
Clinical Research of West Florida, Clearwater, Florida, United States
🇺🇸
Louisiana State University Health Sciences Center-Shreveport, Shreveport, Louisiana, United States
🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States

and more 18 locations

Phase I Study of MEDI522 in Patients With Irinotecan-Refractory Advanced Colorectal Cancer

Phase 1

Completed

Conditions: Cancer

Interventions: Drug: MEDI-522

First Posted Date: 2006-02-01

Last Posted Date: 2008-05-29

Lead Sponsor: MedImmune LLC

Target Recruit Count: 17

Registration Number: NCT00284817

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy